| Date Filed | Type | Description |
| 12/17/2020 |
GN
| BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors |
| 03/02/2020 |
GN
| The Rosen Law Firm P.A. and Bronstein Gewirtz & Grossman, LLC Announce Proposed Class Action Settlement on Behalf of Purchasers of Securities of Spectrum Pharmaceuticals, Inc. -- SPPI |
| 10/24/2018 |
GN
| Analysis: Positioning to Benefit within Spectrum Pharmaceuticals, Carnival, Cadence Design, Tandem Diabetes Care, Rigel Pharmaceuticals, and Regeneron Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results |
| 08/31/2018 |
GN
| Report: Exploring Fundamental Drivers Behind International Bancshares, Morgan Stanley, Equity Residential, Hormel Foods, Spectrum Pharmaceuticals, and Cousins Properties — New Horizons, Emerging Trends, and Upcoming Developments |
| 08/28/2018 |
GN
| AVANT DIAGNOSTICS ADDS TWO ESTEEMED, INTERNATIONALLY RECOGNIZED BOARD MEMBERS AND FILES ITS 2016 10-K IN PREPARATION OF GETTING CURRENT WITH THE SEC |
| 07/27/2018 |
GN
| New Research: Key Drivers of Growth for ICU Medical, A. Schulman, Verso, Eli Lilly, Spectrum Pharmaceuticals, and Intuit — Factors of Influence, Major Initiatives and Sustained Production |
| 02/21/2018 |
GN
| New Research Coverage Highlights Acacia Research, Zebra Technologies, VSE, Spectrum Pharmaceuticals, Agenus, and Williams Companies — Consolidated Revenues, Company Growth, and Expectations for 2018 |
| 12/05/2017 |
GN
| Investor Expectations to Drive Momentum within Spectrum Pharmaceuticals, Agenus, Williams Companies, Acacia Research, Zebra Technologies, and Diodes — Discovering Underlying Factors of Influence |
| 11/07/2017 |
GN
| Recent Analysis Shows Philip Morris, Danaher, Skechers, Sally Beauty, Spectrum Pharma, and Textron Market Influences – Renewed Outlook, Key Drivers of Growth |
| 06/20/2011 |
BW
| Spectrum Pharmaceuticals' ZEVALIN® Was Highlighted During Oral Presentations and Abstracts at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland |
| 05/31/2011 |
BW
| Spectrum Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference |
| 05/23/2011 |
BW
| Spectrum Pharmaceuticals Announces ZEVALIN® and Belinostat Abstracts to Be Presented at the American Society of Clinical Oncology Annual Meeting |
| 05/12/2011 |
BW
| Spectrum Pharmaceuticals' Chairman and Chief Executive Officer Named Ernst & Young Entrepreneur of the Year® Regional Award Finalist |
| 05/04/2011 |
BW
| Spectrum Pharmaceuticals Reports Record Profit and Record Revenue for First Quarter 2011, a Four-Fold Revenue Increase over First Quarter 2010 |
| 04/29/2011 |
BW
| FDA Approves FUSILEV® for Use in Patients with Colorectal Cancer |
| 04/27/2011 |
BW
| Spectrum Pharmaceuticals Announces Record Revenue and Record Profit in First Quarter 2011 |
| 04/21/2011 |
BW
| Spectrum Pharmaceuticals Announces FDA Approval of FUSILEV®'s Ready-to-Use Formulation (RTU) |
| 03/28/2011 |
BW
| Independent Data Monitoring Committee Recommends Continuation of Spectrum Pharmaceuticals' Pivotal Registrational Study of Belinostat in Peripheral T-Cell Lymphoma |
| 03/22/2011 |
BW
| FDA Accepts for Review Spectrum Pharmaceuticals' ZEVALIN® Submission for the Removal of the Bioscan |
| 03/11/2011 |
BW
| Spectrum Pharmaceuticals to Present at the 23rd Annual ROTH OC Growth Stock Conference |
| 03/10/2011 |
BW
| Spectrum Pharmaceuticals Reports Profitable Fourth Quarter and Record Revenue Growth for 2010 |
| 03/07/2011 |
BW
| Spectrum Pharmaceuticals Announces Date and Time for Fourth Quarter and Fiscal 2010 Corporate Update Conference Call |
| 03/02/2011 |
BW
| Spectrum Pharmaceuticals to Present at the 31st Annual Cowen and Company Health Care Conference |
| 02/25/2011 |
BW
| Spectrum Pharmaceuticals to Present at the RBC Capital Markets 2011 Health Care Investor Conference |
| 02/24/2011 |
BW
| Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, as Vice President of Clinical Development |
| 02/23/2011 |
BW
| Spectrum Pharmaceuticals to Present at the Citi Investment Research 2011 Global Health Care Investor Conference |
| 02/15/2011 |
BW
| Spectrum Pharmaceuticals Announces Record Revenue Growth in Fourth Quarter and Fiscal Year 2010; Ends Year with $104 Million in Cash, Cash Equivalents and Investments |
| 12/07/2010 |
BW
| ZEVALIN Data as Preparatory Regimen Presented Prior to Autologous and Allogeneic Stem Cell Transplantation in the Treatment of Non-Hodgkin's Lymphoma |
| 12/06/2010 |
BW
| Single Dose ZEVALIN in First-Ever Phase 2 Monotherapy Trial for Non-Hodgkin's Lymphoma Shows Significant and Durable Clinical Responses |
| 12/06/2010 |
BW
| ZEVALIN Demonstrates 35-Month Progression-Free Survival Benefit after Single Dose in Patients with Non-Hodgkin's Lymphoma |
| 11/30/2010 |
BW
| Spectrum Pharmaceuticals Board Approves Replacement of Stockholder Rights Agreement |
| 11/15/2010 |
BW
| Spectrum Pharmaceuticals Announces Presentation of Eleven (11) Key ZEVALIN Abstracts & Papers at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida on December 4-7, 2010 |
| 11/04/2010 |
BW
| Spectrum Pharmaceuticals Announces Third Quarter 2010 Financial and Operating Results |
| 10/12/2010 |
BW
| Spectrum Pharmaceuticals Announces Appointment of Brett L. Scott as Senior Vice President and Acting Chief Financial Officer |
|